Table of Contents
Thrombosis
Volume 2012 (2012), Article ID 173124, 15 pages
http://dx.doi.org/10.1155/2012/173124
Review Article

Aspirin: Pharmacology and Clinical Applications

Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, 309 East Second Street, Pomona, CA 91766, USA

Received 14 June 2011; Accepted 3 October 2011

Academic Editor: Christian Doutremepuich

Copyright © 2012 Enma V. Paez Espinosa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Bizzozero, “Ueber einen neuen formbestandtheil des blutes und dessen rolle bei der thrombose und der blutgerinnung—untersuchungen,” Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin, vol. 90, no. 2, pp. 261–332, 1882. View at Publisher · View at Google Scholar
  2. S. R. Hanson and S. J. Slichter, “Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement,” Blood, vol. 66, no. 5, pp. 1105–1109, 1985. View at Google Scholar · View at Scopus
  3. B. S. Coller and S. J. Shattil, “The GPIIb/IIIa (integrin {alpha}IIb{beta}3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend,” Blood, vol. 112, no. 8, pp. 3011–3025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. S. Smyth, D. S. Woulfe, J. I. Weitz et al., “G-protein-coupled receptors as signaling targets for antiplatelet therapy,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 449–457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Boilard, P. A. Nigrovic, K. Larabee et al., “Platelets amplify inflammation in arthritis via collagen-dependent microparticle production,” Science, vol. 327, no. 5965, pp. 580–583, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Leslie, “Beyond clotting: the powers of platelets,” Science, vol. 328, no. 5978, pp. 562–564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. G. White, M. D. Krumwiede, and G. Escolar, “Glycoprotein Ib is homogeneously distributed on external and internal membranes of resting platelets,” American Journal of Pathology, vol. 155, no. 6, pp. 2127–2134, 1999. View at Google Scholar · View at Scopus
  8. J. G. White and C. C. Clawson, “The surface-connected canalicular system of blood platelets—a fenestrated membrane system,” American Journal of Pathology, vol. 101, no. 2, pp. 353–364, 1980. View at Google Scholar · View at Scopus
  9. F. Rendu and B. Brohard-Bohn, “The platelet release reaction: granules' constituents, secretion and functions,” Platelets, vol. 12, no. 5, pp. 261–273, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Ebbeling, C. Robertson, A. McNicol, and J. M. Gerrard, “Rapid ultrastructural changes in the dense tubular system following platelet activation,” Blood, vol. 80, no. 3, pp. 718–723, 1992. View at Google Scholar · View at Scopus
  11. T. H. Spaet, Progress in Hemostasis and Thrombosis, vol. 2, Grune & Stratton, New York, NY, USA, 1974.
  12. J. G. White, “Electron opaque structures in human platelets: which are or are not dense bodies?” Platelets, vol. 19, no. 6, pp. 455–466, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Davì and C. Patrono, “Mechanisms of disease: platelet activation and atherothrombosis,” The New England Journal of Medicine, vol. 357, no. 24, pp. 2482–2494, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Fujimura, K. Titani, L. Z. Holland et al., “Von Willebrand factor: a reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib,” Journal of Biological Chemistry, vol. 261, no. 1, pp. 381–385, 1986. View at Google Scholar
  15. D. Varga-Szabo, I. Pleines, and B. Nieswandt, “Cell adhesion mechanisms in platelets,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 3, pp. 403–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Savage, E. Saldívar, and Z. M. Ruggeri, “Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor,” Cell, vol. 84, no. 2, pp. 289–297, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. R. E. Rumbaut, J. K. Randhawa, C. W. Smith, and A. R. Burns, “Mouse cremaster venules are predisposed to light/dye-induced thrombosis independent of wall shear rate, CD18, ICAM-1, or P-selectin,” Microcirculation, vol. 11, no. 3, pp. 239–247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Konstantinides, J. Ware, P. Marchese, F. Almus-Jacobs, D. J. Loskutoff, and Z. M. Ruggeri, “Distinct antithrombotic consequences of platelet glycoprotein Ibα and VI deficiency in a mouse model of arterial thrombosis,” Journal of Thrombosis and Haemostasis, vol. 4, no. 9, pp. 2014–2021, 2006. View at Publisher · View at Google Scholar
  19. Z. M. Ruggeri, J. N. Orje, R. Habermann, A. B. Federici, and A. J. Reininger, “Activation-independent platelet adhesion and aggregation under elevated shear stress,” Blood, vol. 108, no. 6, pp. 1903–1910, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Mailhac, J. J. Badimon, J. T. Fallon et al., “Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution of fibrin(ogen) and platelets,” Circulation, vol. 90, no. 2, pp. 988–996, 1994. View at Google Scholar · View at Scopus
  21. P. A. Whiss, R. G. G. Andersson, and U. Srinivas, “Modulation of P-selectin expression on isolated human platelets by an NO donor assessed by a novel ELISA application,” Journal of Immunological Methods, vol. 200, no. 1-2, pp. 135–143, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Merten and P. Thiagarajan, “P-selectin expression on platelets determines size and stability of platelet aggregates,” Circulation, vol. 102, no. 16, pp. 1931–1936, 2000. View at Google Scholar · View at Scopus
  23. M. Merten and P. Thiagarajan, “P-selectin in arterial thrombosis,” Zeitschrift fur Kardiologie, vol. 93, no. 11, pp. 855–863, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. R. K. Andrews, E. E. Gardiner, Y. Shen, J. C. Whisstock, and M. C. Berndt, “Glycoprotein Ib-IX-V,” International Journal of Biochemistry and Cell Biology, vol. 35, no. 8, pp. 1170–1174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Pham and J. Wang, “Bernard-Soulier syndrome: an inherited platelet disorder,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 12, pp. 1834–1836, 2007. View at Google Scholar · View at Scopus
  26. B. S. Coller, E. I. Peerschke, L. E. Scudder, and C. A. Sullivan, “Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor,” Blood, vol. 61, no. 1, pp. 99–110, 1983. View at Google Scholar · View at Scopus
  27. K. Niiya, E. Hodson, R. Bader et al., “Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation,” Blood, vol. 70, no. 2, pp. 475–483, 1987. View at Google Scholar · View at Scopus
  28. J. S. Bennett, “Structure and function of the platelet integrin αIIbβ 3,” Journal of Clinical Investigation, vol. 115, no. 12, pp. 3363–3369, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Thomas and R. P. Giugliano, “Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe,” Journal of Cardiovascular Pharmacology, vol. 51, no. 5, pp. 425–433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. G. F. Guidetti, B. Bernardi, A. Consonni et al., “Integrin α2β1 induces phosphorylation-dependent and phosphorylation-independent activation of phospholipase Cγ2 in platelets: role of Src kinase and Rac GTPase,” Journal of Thrombosis and Haemostasis, vol. 7, no. 7, pp. 1200–1206, 2009. View at Publisher · View at Google Scholar
  31. H. Suzuki, K. Murasaki, K. Kodama, and H. Takayama, “Intracellular localization of glycoprotein VI in human platelets and its surface expression upon activation,” British Journal of Haematology, vol. 121, no. 6, pp. 904–912, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Moroi and S. M. Jung, “Platelet glycoprotein VI: its structure and function,” Thrombosis Research, vol. 114, no. 4, pp. 221–233, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Kim, P. Mangin, C. Dangelmaier et al., “Role of phosphoinositide 3-kinase β in glycoprotein VI-mediated Akt activation in platelets,” Journal of Biological Chemistry, vol. 284, no. 49, pp. 33763–33772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Gibbins, J. Asselin, R. Farndale, M. Barnes, C. L. Law, and S. P. Watson, “Tyrosine phosphorylation of the Fc receptor γ-chain in collagen- stimulated platelets,” Journal of Biological Chemistry, vol. 271, no. 30, pp. 18095–18099, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. J. F. Arthur, S. Dunkley, and R. K. Andrews, “Platelet glycoprotein VI-related clinical defects,” British Journal of Haematology, vol. 139, no. 3, pp. 363–372, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Varga-Szabo, A. Braun, and B. Nieswandt, “Calcium signaling in platelets,” Journal of Thrombosis and Haemostasis, vol. 7, no. 7, pp. 1057–1066, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Murugappan, H. Shankar, and S. P. Kunapuli, “Platelet receptors for adenine nucleotides and thromboxane A2,” Seminars in Thrombosis and Hemostasis, vol. 30, no. 4, pp. 411–418, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. R. J. Gryglewski, “Prostacyclin among prostanoids,” Pharmacological Reports, vol. 60, no. 1, pp. 3–11, 2008. View at Google Scholar · View at Scopus
  39. J. E. B. Fox, “Cytoskeletal proteins and platelet signaling,” Thrombosis and Haemostasis, vol. 86, no. 1, pp. 198–213, 2001. View at Google Scholar
  40. G. Escolar, M. Krumwiede, and J. G. White, “Organization of the actin cytoskeleton of resting and activated platelets in suspension,” American Journal of Pathology, vol. 123, no. 1, pp. 86–94, 1986. View at Google Scholar · View at Scopus
  41. J. L. Daniel, I. R. Molish, M. Rigmaiden, and G. Stewart, “Evidence for a role of myosin phosphorylation in the initiation of the platelet shape change response,” Journal of Biological Chemistry, vol. 259, no. 15, pp. 9826–9831, 1984. View at Google Scholar · View at Scopus
  42. L. K. Jennings, J. E. B. Fox, H. H. Edwards, and D. R. Phillips, “Changes in the cytoskeletal structure of human platelets following thrombin activation,” Journal of Biological Chemistry, vol. 256, no. 13, pp. 6927–6932, 1981. View at Google Scholar · View at Scopus
  43. K. Broos, H. B. Feys, S. F. De Meyer, K. Vanhoorelbeke, and H. Deckmyn, “Platelets at work in primary hemostasis,” Blood Reviews, vol. 25, no. 4, pp. 155–167, 2011. View at Publisher · View at Google Scholar
  44. P. Blair and R. Flaumenhaft, “Platelet α-granules: basic biology and clinical correlates,” Blood Reviews, vol. 23, no. 4, pp. 177–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Sehgal and B. Storrie, “Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release,” Journal of Thrombosis and Haemostasis, vol. 5, no. 10, pp. 2009–2016, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. T. Nurden and P. Nurden, “The gray platelet syndrome: clinical spectrum of the disease,” Blood Reviews, vol. 21, no. 1, pp. 21–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. D. M. Maynard, H. F.G. Heijnen, M. K. Horne, J. G. White, and W. A. Gahl, “Proteomic analysis of platelet α-granules using mass spectrometry,” Journal of Thrombosis and Haemostasis, vol. 5, no. 9, pp. 1945–1955, 2007. View at Publisher · View at Google Scholar
  48. W. P. Fay, J. G. Murphy, and W. G. Owen, “High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 10, pp. 1277–1284, 1996. View at Google Scholar · View at Scopus
  49. B. N. Kahner, H. Shankar, S. Murugappan, G. L. Prasad, and S. P. Kunapuli, “Nucleotide receptor signaling in platelets,” Journal of Thrombosis and Haemostasis, vol. 4, no. 11, pp. 2317–2326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Offermanns, C. F. Toombs, Y. H. Hu, and M. I. Simon, “Defective platelet activation in Gα(q)-deficient mice,” Nature, vol. 389, no. 6647, pp. 183–186, 1997. View at Publisher · View at Google Scholar · View at Scopus
  51. R. T. Dorsam and S. P. Kunapuli, “Central role of the P2Y12 receptor in platelet activation,” Journal of Clinical Investigation, vol. 113, no. 3, pp. 340–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. R. F. Storey, H. M. Judge, R. G. Wilcox, and S. Heptinstall, “Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin,” Thrombosis and Haemostasis, vol. 88, no. 3, pp. 488–494, 2002. View at Google Scholar · View at Scopus
  53. J. Jin, T. M. Quinton, J. Zhang, S. E. Rittenhouse, and S. P. Kunapuli, “Adenosine diphosphate (ADP)-induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin αIIbβ3 and ADP receptors,” Blood, vol. 99, no. 1, pp. 193–198, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. G. A. FitzGerald, “Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists,” American Journal of Cardiology, vol. 68, no. 7, pp. 11B–15B, 1991. View at Google Scholar · View at Scopus
  55. M. Huizing, Y. Anikster, and W. A. Gahl, “Hermansky-Pudlak syndrome and Chediak-Higashi syndrome: disorders of vesicle formation and trafficking,” Thrombosis and Haemostasis, vol. 86, no. 1, pp. 233–245, 2001. View at Google Scholar · View at Scopus
  56. M. L. Wei, “Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function,” Pigment Cell Research, vol. 19, no. 1, pp. 19–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Li, M. E. Rusiniak, S. Chintala, R. Gautam, E. K. Novak, and R. T. Swank, “Murine Hermansky-Pudlak syndrome genes: regulators of lysosome-related organelles,” BioEssays, vol. 26, no. 6, pp. 616–628, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. Karim, D. L. Nagle, H. H. Kandil, J. Bürger, K. J. Moore, and R. A. Spritz, “Mutations in the Chediak-Higashi syndrome gene (CHS1) indicate requirement for the complete 3801 amino acid CHS protein,” Human Molecular Genetics, vol. 6, no. 7, pp. 1087–1089, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Rendu, J. Breton Gorius, M. Lebert et al., “Evidence that abnormal platelet functions in human Chediak-Higashi syndrome are the result of a lack of dense bodies,” American Journal of Pathology, vol. 111, no. 3, pp. 307–314, 1983. View at Google Scholar
  60. S. Ciferri, C. Emiliani, G. Guglielmini, A. Orlacchio, G. G. Nenci, and P. Gresele, “Platelets release their lysosomal content in vivo in humans upon activation,” Thrombosis and Haemostasis, vol. 83, no. 1, pp. 157–164, 2000. View at Google Scholar · View at Scopus
  61. D. Blockmans, H. Deckmyn, and J. Vermylen, “Platelet activation,” Blood Reviews, vol. 9, no. 3, pp. 143–156, 1995. View at Google Scholar · View at Scopus
  62. Y. Ikeda, M. Handa, K. Kawano et al., “The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress,” Journal of Clinical Investigation, vol. 87, no. 4, pp. 1234–1240, 1991. View at Google Scholar · View at Scopus
  63. L. F. Brass, D. R. Manning, K. Cichowski, and C. S. Abrams, “Signaling through G proteins in platelets: to the integrins and beyond,” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 581–589, 1997. View at Google Scholar · View at Scopus
  64. B. Nieswandt and S. P. Watson, “Platelet-collagen interaction: is GPVI the central receptor?” Blood, vol. 102, no. 2, pp. 449–461, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. R. W. Farndale, J. J. Sixma, M. J. Barnes, and P. G. de Groot, “The role of collagen in thrombosis and hemostasis,” Journal of Thrombosis and Haemostasis, vol. 2, no. 4, pp. 561–573, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Nieswandt, C. Brakebusch, W. Bergmeier et al., “Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen,” EMBO Journal, vol. 20, no. 9, pp. 2120–2130, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. J. M. Clemetson, J. Polgar, E. Magnenat, T. N. C. Wells, and K. J. Clemetson, “The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcαR and the natural killer receptors,” Journal of Biological Chemistry, vol. 274, no. 41, pp. 29019–29024, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. P. R. M. Siljander, I. C. A. Munnix, P. A. Smethurst et al., “Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood,” Blood, vol. 103, no. 4, pp. 1333–1341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. R. F. Storey, H. M. Sanderson, A. E. White, J. A. May, K. E. Cameron, and S. Heptinstall, “The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity,” British Journal of Haematology, vol. 110, no. 4, pp. 925–934, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. A. K. Vine, “Recent advances in haemostasis and thrombosis,” Retina, vol. 29, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Schenone, B. C. Furie, and B. Furie, “The blood coagulation cascade,” Current Opinion in Hematology, vol. 11, no. 4, pp. 272–277, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Ajjan and P. J. Grant, “Coagulation and atherothrombotic disease,” Atherosclerosis, vol. 186, no. 2, pp. 240–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Kalafatis, N. A. Swords, M. D. Rand, and K. G. Mann, “Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes,” Biochimica et Biophysica Acta, vol. 1227, no. 3, pp. 113–129, 1994. View at Publisher · View at Google Scholar · View at Scopus
  74. A. J. Schroit and R. F. A. Zwaal, “Transbilayerd movement of phospholipids in red cell and platelet membranes,” Biochimica et Biophysica Acta, vol. 1071, no. 3, pp. 313–329, 1991. View at Publisher · View at Google Scholar
  75. S. S. Ahmad, R. Rawala-Sheikh, and P. N. Walsh, “Components and assembly of the factor X activating complex,” Seminars in Thrombosis and Hemostasis, vol. 18, no. 3, pp. 311–323, 1992. View at Google Scholar
  76. H. J. Weiss, W. J. Vicic, B. A. Lages, and J. Rogers, “Isolated deficiency of platelet procoagulant activity,” American Journal of Medicine, vol. 67, no. 2, pp. 206–213, 1979. View at Google Scholar · View at Scopus
  77. J. Rosing, E. M. Bevers, P. Comfurius et al., “Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder,” Blood, vol. 65, no. 6, pp. 1557–1561, 1985. View at Google Scholar
  78. N. Crawford, “The presence of contractile proteins in platelet microparticles isolated from human and animal platelet-free plasma,” British Journal of Haematology, vol. 21, no. 1, pp. 53–69, 1971. View at Google Scholar · View at Scopus
  79. J. N. George, E. B. Pickett, and S. Saucerman, “Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery,” Journal of Clinical Investigation, vol. 78, no. 2, pp. 340–348, 1986. View at Google Scholar
  80. T. E. Warkentin and J. I. Sheppard, “Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists,” Platelets, vol. 10, no. 5, pp. 319–326, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Galli, E. M. Bevers, P. Comfurius, T. Barbui, and R. F. A. Zwaal, “Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles,” British Journal of Haematology, vol. 83, no. 3, pp. 466–472, 1993. View at Google Scholar · View at Scopus
  82. Y. J. Lee, W. Jy, L. L. Horstman et al., “Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multi-infarct dementias,” Thrombosis Research, vol. 72, no. 4, pp. 295–304, 1993. View at Publisher · View at Google Scholar · View at Scopus
  83. J. G. Kelton, T. E. Warkentin, C. P. M. Hayward, W. G. Murphy, and J. C. Moore, “Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles,” Blood, vol. 80, no. 9, pp. 2246–2251, 1992. View at Google Scholar · View at Scopus
  84. S. Falati, Q. Liu, P. Gross et al., “Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin,” Journal of Experimental Medicine, vol. 197, no. 11, pp. 1585–1598, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Kumar, M. P. Villani, U. K. Patel, J. C. Keith Jr., and R. G. Schaub, “Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model,” Circulation, vol. 99, no. 10, pp. 1363–1369, 1999. View at Google Scholar · View at Scopus
  86. R. Altman, L. Carreras, R. Diaz et al., “Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,” British Medical Journal, vol. 308, no. 6921, pp. 81–106, 1994. View at Google Scholar · View at Scopus
  87. P. L. Gross and J. I. Weitz, “New antithrombotic drugs,” Clinical Pharmacology and Therapeutics, vol. 86, no. 2, pp. 139–146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Gaussem, J. L. Reny, C. Thalamas et al., “The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies,” Journal of Thrombosis and Haemostasis, vol. 3, no. 7, pp. 1437–1445, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. J. R. Vane, “Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs,” Nature: New biology, vol. 231, no. 25, pp. 232–235, 1971. View at Google Scholar · View at Scopus
  90. J. B. Smith and A. L. Willis, “Aspirin selectively inhibits prostaglandin production in human platelets,” Nature: New biology, vol. 231, no. 25, pp. 235–237, 1971. View at Google Scholar · View at Scopus
  91. S. H. Ferreira, S. Moncada, and J. R. Vane, “Indomethacin and aspirin abolish prostaglandin release from the spleen,” Nature: New biology, vol. 231, no. 25, pp. 237–239, 1971. View at Google Scholar · View at Scopus
  92. A. S. Milton and S. Wendlandt, “A possible role for prostaglandin E1 as a modulator for temperature regulation in the central nervous system of the cat,” Journal of Physiology, vol. 207, no. 2, pp. 76P–77P, 1970. View at Google Scholar · View at Scopus
  93. L. M. Solomon, L. Juhlin, and M. B. Kirschenbaum, “Prostaglandin on cutaneous vasculature,” Journal of Investigative Dermatology, vol. 51, no. 4, pp. 280–282, 1968. View at Google Scholar · View at Scopus
  94. M. Hemler, W. E. M. Lands, and W. L. Smith, “Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme,” Journal of Biological Chemistry, vol. 251, no. 18, pp. 5575–5579, 1976. View at Google Scholar · View at Scopus
  95. D. L. DeWitt and W. L. Smith, “Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 5, pp. 1412–1416, 1988. View at Google Scholar · View at Scopus
  96. T. Miyamoto, N. Ogino, S. Yamamoto, and O. Hayaishi, “Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes,” Journal of Biological Chemistry, vol. 251, no. 9, pp. 2629–2636, 1976. View at Google Scholar · View at Scopus
  97. J. A. Mitchell, P. Akarasereenont, C. Thiemermann, R. J. Flower, and J. R. Vane, “Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11693–11697, 1993. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Picot, P. J. Loll, and R. M. Garavito, “The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1,” Nature, vol. 367, no. 6460, pp. 243–249, 1994. View at Publisher · View at Google Scholar · View at Scopus
  99. G. J. Roth, N. Stanford, and J. W. Jacobs, “Acetylation of prostaglandin synthetase by aspirin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 2, no. 8, pp. 3073–3307, 19755. View at Google Scholar
  100. O. Vesterqvist and K. Green, “Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions,” Prostaglandins, vol. 27, no. 4, pp. 627–644, 1984. View at Publisher · View at Google Scholar · View at Scopus
  101. W. Xie, J. G. Chipman, D. L. Robertson, R. L. Erikson, and D. L. Simmons, “Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 7, pp. 2692–2696, 1991. View at Google Scholar · View at Scopus
  102. R. G. Kurumbail, A. M. Stevens, J. K. Gierse et al., “Structural basis for selective inhibition of cyciooxygenase-2 by anti-inflammatory agents,” Nature, vol. 384, no. 6610, pp. 644–648, 1996. View at Google Scholar · View at Scopus
  103. C. Luong, A. Miller, J. Barnett, J. Chow, C. Ramesha, and M. F. Browner, “Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2,” Nature Structural Biology, vol. 3, no. 11, pp. 927–933, 1996. View at Publisher · View at Google Scholar · View at Scopus
  104. J. A. Mancini, G. P. O'Neill, C. Bayly, and P. J. Vickers, “Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis,” FEBS Letters, vol. 342, no. 1, pp. 33–37, 1994. View at Publisher · View at Google Scholar · View at Scopus
  105. N. V. Chandrasekharan, H. Dai, K. L. T. Roos et al., “COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13926–13931, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. J. P. Courade, D. Besse, C. Delchambre et al., “Acetaminophen distribution in the rat central nervous system,” Life Sciences, vol. 69, no. 12, pp. 1455–1464, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Ueno, M. Kodali, A. Tello-Montoliu, and D. J. Angiolillo, “Role of platelets and antiplatelet therapy in cardiovascular disease,” Journal of Atherosclerosis and Thrombosis, vol. 18, no. 6, pp. 431–442, 2011. View at Publisher · View at Google Scholar
  108. Antithrombotic Trialists' (ATT) Collaboration, “Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials,” The Lancet, vol. 373, no. 9678, pp. 1849–1860, 2009. View at Publisher · View at Google Scholar
  109. S. R. Mehta, J. P. Bassand, S. Chrolavicius et al., “Dose comparisons of clopidogrel and aspirin in acute coronary syndromes,” The New England Journal of Medicine, vol. 363, no. 10, pp. 930–942, 2010. View at Publisher · View at Google Scholar
  110. F. T. Khasawneh, J. S. Huang, F. Mir, S. Srinivasan, C. Tiruppathi, and G. C. le Breton, “Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF2α with the thromboxane A2 receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets,” Biochemical Pharmacology, vol. 75, no. 12, pp. 2301–2315, 2008. View at Publisher · View at Google Scholar
  111. J. L. Cracowski, T. Durand, and G. Bessard, “Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications,” Trends in Pharmacological Sciences, vol. 23, no. 8, pp. 360–366, 2002. View at Publisher · View at Google Scholar · View at Scopus
  112. C. P. Martin and R. L. Talbert, “Aspirin resistance: an evaluation of current evidence and measurement methods,” Pharmacotherapy, vol. 25, no. 7, pp. 942–953, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. J. J. Calvete, “On the structure and function of platelet integrin α(IIb)β3, the fibrinogen receptor,” Proceedings of the Society for Experimental Biology and Medicine, vol. 208, no. 4, pp. 346–360, 1995. View at Google Scholar · View at Scopus
  114. T. Goodman, A. Ferro, and P. Sharma, “Pharmacogenetics of aspirin resistance: a comprehensive systematic review,” British Journal of Clinical Pharmacology, vol. 66, no. 2, pp. 222–332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. J. A. G. Agúndez, C. Martínez, D. Pérez-Sala, M. Carballo, M. J. Torres, and E. García-Martín, “Pharmacogenomics in aspirin intolerance,” Current Drug Metabolism, vol. 10, no. 9, pp. 998–1008, 2009. View at Publisher · View at Google Scholar
  116. Q. Li, B. L. Chen, V. Ozmedir et al., “Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a chinese population and association with attenuated response to aspirin,” Pharmacogenomics, vol. 8, no. 6, pp. 577–586, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. S. C. Smith Jr., J. Allen, S. N. Blair et al., “AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the national heart, lung, and blood institute,” Journal of the American College of Cardiology, vol. 47, no. 10, pp. 2130–2139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. N. Calonge, D. B. Petitti, T. G. DeWitt et al., “Aspirin for the prevention of cardiovascular disease: U.S. preventive services task force recommendation statement,” Annals of Internal Medicine, vol. 150, no. 6, pp. 396–404, 2009. View at Google Scholar · View at Scopus
  119. W. F. Miser, “Controversies in family medicine,” American Family Physician, vol. 83, no. 12, pp. 1380–1386, 2011. View at Google Scholar
  120. G. de Berardis, M. Sacco, G. F. Strippoli et al., “Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials,” BMJ, vol. 339, p. b4531, 2009. View at Publisher · View at Google Scholar
  121. G. de Berardis, M. Sacco, G. F.M. Strippoli et al., “Erratum: aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials,” BMJ, vol. 340, p. C374, 2009. View at Google Scholar
  122. P. M. Ridker, N. R. Cook, I. M. Lee et al., “A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women,” The New England Journal of Medicine, vol. 352, no. 13, pp. 1293–1304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. F. K. L. Chan, S. C. S. Chung, B. Y. Suen et al., “Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen,” The New England Journal of Medicine, vol. 344, no. 13, pp. 967–973, 2001. View at Publisher · View at Google Scholar · View at Scopus
  124. J. J. Y. Sung, J. Y. W. Lau, J. Y. L. Ching et al., “Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial,” Annals of Internal Medicine, vol. 152, no. 1, pp. 1–9, 2010. View at Google Scholar · View at Scopus
  125. Z. Chen, P. Sandercock, H. Pan et al., “Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial,” Stroke, vol. 31, no. 6, pp. 1240–1249, 2000. View at Google Scholar
  126. J. P. Kelly, D. W. Kaufman, J. M. Jurgelon, J. Sheehan, R. S. Koff, and S. Shapiro, “Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product,” The Lancet, vol. 348, no. 9039, pp. 1413–1416, 1996. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Pignone, G. K. Anderson, K. Binns, H. H. Tilson, and S. M. Weisman, “Aspirin use among adults aged 40 and older in the United States. Results of a national survey,” American Journal of Preventive Medicine, vol. 32, no. 5, pp. 403–407, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, and C. Patrono, “Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials,” British Medical Journal, vol. 332, no. 7553, pp. 1302–1308, 2006. View at Google Scholar · View at Scopus
  129. J. S. Bennett, A. Daugherty, D. Herrington, P. Greenland, and H. Roberts, “The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association,” Circulation, vol. 111, no. 13, pp. 1713–1716, 2005. View at Publisher · View at Google Scholar
  130. J. S. Bennett, A. Daugherty, D. Herrington, P. Greenland, and H. Roberts, “Erratum: the use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association,” Circulation, vol. 111, p. 1717, 2005. View at Publisher · View at Google Scholar
  131. E. M. Smyth, “Thromboxane and the thromboxane receptor in cardiovascular disease,” Clinical Lipidology, vol. 5, no. 2, pp. 209–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Patrono, L. A. García Rodríguez, R. Landolfi, and C. Baigent, “Low-dose aspirin for the prevention of atherothrombosis,” The New England Journal of Medicine, vol. 353, no. 22, pp. 2373–2383, 2005. View at Publisher · View at Google Scholar
  133. S. Mcphee, M. Pappadakis, and M. W. Ravow, Current Medical Diagnosis and Treatment, Mc-Graw Hill, New York, NY, USA, 15th edition, 2011.
  134. S. H. Meves, H. Neubauer, U. Overbeck, and H. G. Endres, “Is there an ideal way to initiate antiplatelet therapy with aspirin? A crossover study on healthy volunteers evaluating different dosing schemes with whole blood aggregometry,” BMC Research Notes, vol. 4, p. 106, 2011. View at Publisher · View at Google Scholar
  135. J. K. Liao, “Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?” Circulation, vol. 115, no. 12, pp. 1615–1621, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. Z. M. Chen, “CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke,” The Lancet, vol. 349, no. 9066, pp. 1641–1649, 1997. View at Publisher · View at Google Scholar
  137. P. A. G. Sandercock, “The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke,” The Lancet, vol. 349, no. 9065, pp. 1569–1581, 1997. View at Publisher · View at Google Scholar
  138. “Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials,” Archives of Internal Medicine, vol. 154, no. 13, pp. 1449–1457, 1994. View at Publisher · View at Google Scholar · View at Scopus
  139. E. C. Stecker, “Finding a balance in long-term anticoagulation therapy,” The American Journal of Managed Care, vol. 16, no. 10, pp. S278–S283, 2010. View at Google Scholar
  140. R. G. Hart, L. A. Pearce, and M. I. Aguilar, “Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation,” Annals of Internal Medicine, vol. 146, no. 12, pp. 857–867, 2007. View at Google Scholar · View at Scopus
  141. D. E. Singer, G. W. Albers, J. E. Dalen et al., “Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, pp. 546S–592S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. K. E. J. Airaksinen, H. Suurmunne, P. Porela et al., “Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting,” American Journal of Cardiology, vol. 106, no. 2, pp. 175–179, 2010. View at Publisher · View at Google Scholar
  143. H. Neubauer, A. F. C. Kaiser, H. G. Endres et al., “Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance—the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy,” BMC Medicine, vol. 12, no. 9, p. 3, 2011. View at Publisher · View at Google Scholar